Stockscreener 앱 받기
42.70
0.56%
-0.24
시간 외 거래:
42.70
전일 마감가:
$42.94
열려 있는:
$42.83
하루 거래량:
2.56M
Relative Volume:
1.00
시가총액:
$11.09B
수익:
$2.29B
순이익/손실:
$677.90M
주가수익비율:
17.98
EPS:
2.3753
순현금흐름:
$779.77M
1주 성능:
+0.78%
1개월 성능:
-3.09%
6개월 성능:
+12.52%
1년 성능:
+30.18%
1일 변동 폭
$42.35
$43.52
1주일 범위
$40.92
$44.28
52주 변동 폭
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
42.70 | 11.15B | 2.29B | 677.90M | 779.77M | 2.3753 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-11-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis Reports Solid Earnings-Are New Highs Back on the Table? - Finviz
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by LSV Asset Management - MarketBeat
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com India
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com
EXEL: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts - Benzinga
Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00 - MarketBeat
EXEL: Stifel Raises Price Target to $44 and Maintains Hold Ratin - GuruFocus
Exelixis (NASDAQ:EXEL) Price Target Raised to $35.00 - MarketBeat
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus - Yahoo Finance UK
Citizens maintains Exelixis stock rating on promising cancer treatment data By Investing.com - Investing.com Nigeria
RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating - marketscreener.com
Citizens maintains Exelixis stock rating on promising cancer treatment data - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Decoding Exelixis Inc (EXEL): A Strategic SWOT Insight - GuruFocus
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Exelixis Q4 2025 Earnings Call Transcript - MarketBeat
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch - MSN
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics - sharewise.com
Exelixis (EXEL) Reports Strong Q4 2025 Earnings with Robust Grow - GuruFocus
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion By Investing.com - Investing.com South Africa
Exelixis Q4 Earnings Call Highlights - Yahoo Finance
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Upda - PharmiWeb.com
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com
Earnings call transcript: Exelixis Q4 2025 reports EPS beat, stock dips - Investing.com India
Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue - ChartMill
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Exelixis: Q4 Earnings Snapshot - KVUE
Why Exelixis (EXEL) is one of the best healthcare stocks under $50 to invest in - MSN
EXEL: Amended Ipsen deal grants exclusive cabozantinib rights outside U.S./Japan, $200M upfront, royalties - TradingView
EXELIXIS, INC. SEC 10-K Report - TradingView
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.62B - marketscreener.com
Exelixis, Inc. Profit Climbs In Q4 - Nasdaq
Exelixis (NASDAQ:EXEL) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS - MarketBeat
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can zanzalintinib justify valuation? - Investing.com
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In - Yahoo! Finance Canada
Stock Report: Will Exelixis Inc outperform its industry peersBreakout Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD - Finviz
Exelixis (EXEL) Poised for Q4 Earnings Announcement - GuruFocus
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT - MSN
Can Exelixis Inc. stock sustain institutional interestExit Point & Reliable Volume Spike Alerts - mfd.ru
A Peek at Exelixis's Future Earnings - Benzinga
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup - ChartMill
Exelixis (EXEL) Is Up 6.1% After FDA Accepts Colorectal Cancer Combo NDAWhat's Changed - simplywall.st
Aug Big Picture: What is the earnings history of Exelixis Inc2025 Buyback Activity & Consistent Return Investment Signals - baoquankhu1.vn
Exelixis, Inc. $EXEL Shares Sold by Principal Financial Group Inc. - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Raises Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):